Cas No.: | 1202759-32-7 |
Chemical Name: | CNX-774 |
Synonyms: | CNX-774;4-{4-[(4-{[3-(Acryloylamino)phenyl]amino}-5-fluoro-2-pyrimidinyl) amino]phenoxy}-N-methyl-2-pyridinecarboxamide;2H-1-Benzopyran-2-one, 7-methoxy-3-phenyl-4-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-;4-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)-7-methoxy-3-phenyl-2H-chromen-2-one;4-(4-(4-(3-acrylamidophenylamino)-5-fluoropyrimidin-2-ylamino)phenoxy)-N-methylpicolinamide;7-Methoxy-3-phenyl-4-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)coumarin;AC1MI1IO;AC1Q4DT8;AG-H-16605;CHEMBL2413906;CNX774;Coumarin, 7-methoxy-3-phenyl-4-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-;CTK |
SMILES: | O=C(NC)C1=NC=CC(OC2=CC=C(NC3=NC=C(F)C(NC4=CC=CC(NC(C=C)=O)=C4)=N3)C=C2)=C1 |
Formula: | C26H22N7O3F |
M.Wt: | 499.49638 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | CNX-774 is a potent, selective, and orally available small molecule inhibitor of Btk (IC50< 1 nM) that forms a ligand-directed covalent bond with Cys-481, a non-conserved amino acid within the active site of the enzyme. |
References: | [1]. Akinleye A, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59. [2]. In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase |